IL300795A - Compounds as GLP-1R agonists - Google Patents
Compounds as GLP-1R agonistsInfo
- Publication number
- IL300795A IL300795A IL300795A IL30079523A IL300795A IL 300795 A IL300795 A IL 300795A IL 300795 A IL300795 A IL 300795A IL 30079523 A IL30079523 A IL 30079523A IL 300795 A IL300795 A IL 300795A
- Authority
- IL
- Israel
- Prior art keywords
- optionally substituted
- compound
- ring
- alkyl
- halo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068870P | 2020-08-21 | 2020-08-21 | |
| PCT/US2021/047015 WO2022040600A1 (en) | 2020-08-21 | 2021-08-20 | Compounds as glp-1r agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300795A true IL300795A (en) | 2023-04-01 |
Family
ID=80350630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300795A IL300795A (en) | 2020-08-21 | 2021-08-20 | Compounds as GLP-1R agonists |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230322744A1 (enExample) |
| EP (1) | EP4199919A4 (enExample) |
| JP (1) | JP2023538408A (enExample) |
| KR (1) | KR20230074486A (enExample) |
| CN (1) | CN116507326A (enExample) |
| AU (1) | AU2021327397A1 (enExample) |
| BR (1) | BR112023003168A2 (enExample) |
| CA (1) | CA3192601A1 (enExample) |
| CL (2) | CL2023000516A1 (enExample) |
| CO (1) | CO2023003322A2 (enExample) |
| IL (1) | IL300795A (enExample) |
| MX (1) | MX2023002108A (enExample) |
| PE (1) | PE20231206A1 (enExample) |
| TW (1) | TWI905252B (enExample) |
| WO (1) | WO2022040600A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN117645601A (zh) * | 2020-06-10 | 2024-03-05 | 重庆康丁医药技术有限公司 | 一种具有心血管益处的glp-1小分子 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| JP7812052B2 (ja) | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| US20240252492A1 (en) * | 2021-01-28 | 2024-08-01 | Carmot Therapeutics ,Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2022184849A1 (en) * | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| CN116940561B (zh) * | 2021-03-22 | 2026-08-11 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| EP4317145A4 (en) * | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| US20220348564A1 (en) * | 2021-03-24 | 2022-11-03 | Eccogene (Shanghai) Co., Ltd. | Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| US20240360109A1 (en) * | 2021-08-04 | 2024-10-31 | Shanghai Hansoh Biomedical Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
| KR20240056719A (ko) | 2021-09-08 | 2024-04-30 | 시오노기 앤드 컴파니, 리미티드 | 항비만 작용이 관여하는 질환의 예방 및 치료용 의약 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| AU2023224854A1 (en) * | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CA3246495A1 (en) * | 2022-03-25 | 2023-09-28 | Ildong Pharmaceutical Co., Ltd. | NEW GLP-1 RECEPTOR AGONIST COMPOUND SALT, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION INCLUDING IT |
| CN116574092B (zh) * | 2022-05-20 | 2024-08-20 | 成都地奥九泓制药厂 | 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用 |
| CN120289449A (zh) * | 2022-07-18 | 2025-07-11 | 厦门市博瑞来医药科技有限公司 | 一种合成非甾体类fxr调节剂的化合物 |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| US20260098031A1 (en) * | 2022-09-22 | 2026-04-09 | Shionogi & Co., Ltd. | Monocyclic compound having glp-1 receptor agonist activity |
| CN116102543B (zh) * | 2022-10-21 | 2025-07-22 | 江南大学 | 一种glp-1r激动剂、合成方法及其用途 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| KR20250139383A (ko) * | 2023-02-02 | 2025-09-23 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 시클로알켄계 화합물의 염, 결정형 및 이의 제조 방법과 응용 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| EP4780818A1 (en) * | 2023-09-21 | 2026-07-29 | Yunovia Co., Ltd. | Method for preparing substituted fused imidazole derivative |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026092580A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases |
| WO2026092581A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata |
| WO2026092583A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases |
| WO2026151251A1 (ko) * | 2025-01-10 | 2026-07-16 | 유노비아 주식회사 | Glp-1r 작용제를 포함하는 대사성 질환 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3806855T3 (fi) * | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| JP7161605B2 (ja) * | 2018-08-31 | 2022-10-26 | ファイザー・インク | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ |
| EA202191432A1 (ru) * | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| ES3029360T3 (en) * | 2019-11-15 | 2025-06-24 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
| CA3217720A1 (en) * | 2021-05-03 | 2022-11-10 | Xiaohui Du | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| US20240382471A1 (en) * | 2021-07-21 | 2024-11-21 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
-
2021
- 2021-08-20 JP JP2023512462A patent/JP2023538408A/ja not_active Ceased
- 2021-08-20 US US18/042,443 patent/US20230322744A1/en not_active Abandoned
- 2021-08-20 IL IL300795A patent/IL300795A/en unknown
- 2021-08-20 PE PE2023000511A patent/PE20231206A1/es unknown
- 2021-08-20 MX MX2023002108A patent/MX2023002108A/es unknown
- 2021-08-20 BR BR112023003168A patent/BR112023003168A2/pt unknown
- 2021-08-20 US US17/445,588 patent/US20220089578A1/en not_active Abandoned
- 2021-08-20 WO PCT/US2021/047015 patent/WO2022040600A1/en not_active Ceased
- 2021-08-20 TW TW110130936A patent/TWI905252B/zh active
- 2021-08-20 EP EP21859247.5A patent/EP4199919A4/en active Pending
- 2021-08-20 CN CN202180071858.5A patent/CN116507326A/zh active Pending
- 2021-08-20 KR KR1020237009681A patent/KR20230074486A/ko not_active Withdrawn
- 2021-08-20 AU AU2021327397A patent/AU2021327397A1/en active Pending
- 2021-08-20 CA CA3192601A patent/CA3192601A1/en active Pending
-
2023
- 2023-02-21 CL CL2023000516A patent/CL2023000516A1/es unknown
- 2023-03-17 CO CONC2023/0003322A patent/CO2023003322A2/es unknown
-
2024
- 2024-04-05 CL CL2024001025A patent/CL2024001025A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20231206A1 (es) | 2023-08-17 |
| WO2022040600A1 (en) | 2022-02-24 |
| CL2023000516A1 (es) | 2023-10-30 |
| TWI905252B (zh) | 2025-11-21 |
| US20230322744A1 (en) | 2023-10-12 |
| EP4199919A4 (en) | 2024-12-25 |
| TW202227410A (zh) | 2022-07-16 |
| CA3192601A1 (en) | 2022-02-24 |
| AU2021327397A1 (en) | 2023-05-04 |
| CO2023003322A2 (es) | 2023-07-10 |
| BR112023003168A2 (pt) | 2023-05-09 |
| KR20230074486A (ko) | 2023-05-30 |
| US20220089578A1 (en) | 2022-03-24 |
| EP4199919A1 (en) | 2023-06-28 |
| JP2023538408A (ja) | 2023-09-07 |
| AU2021327397A9 (en) | 2024-08-08 |
| CN116507326A (zh) | 2023-07-28 |
| CL2024001025A1 (es) | 2024-10-04 |
| MX2023002108A (es) | 2023-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI905252B (zh) | 作為glp-1r促效劑之化合物 | |
| US12570642B2 (en) | GLP-IR modulating compounds | |
| KR20230173719A (ko) | 카르복시-벤즈이미다졸 glp-1r 조절 화합물 | |
| NZ747914A (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
| TW202317553A (zh) | Glp-1受體激動劑及其組合物和用途 | |
| KR20240005838A (ko) | 포스포닐 유도체 및 이의 조성물과 약학적 응용 | |
| CA2988721A1 (en) | Glp-1 receptor agonists and uses thereof | |
| JP2019509978A (ja) | Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物 | |
| KR20240148000A (ko) | Glp-1r 조절 화합물 | |
| IL322515A (en) | Compounds that inhibit tyrosine kinase activity for use in the treatment of leukemia | |
| AU2019379213B2 (en) | Six-membered fused with six-membered heterocyclic compound and uses thereof serving as protein receptor kinase inhibitor | |
| US12624034B2 (en) | Non-covalent modifiers of AKT1 and uses thereof | |
| EP3704114A1 (en) | Spirocyclic compounds as farnesoid x receptor modulators | |
| IL266312A (en) | Derived from pyrido [4,3-D] pyrimidine and its acceptable pharmacological salt | |
| IL300375A (en) | compounds as C5AR inhibitors | |
| TW202302585A (zh) | 具有四氫吲哚－１－甲醯胺作為ｂｃｌ－２抑制劑之化合物 | |
| KR20230022861A (ko) | Tead 결합제로서 유용한 트리시클릭 헤테로사이클 | |
| JP2025521719A (ja) | ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるその使用 | |
| US20260055057A1 (en) | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof | |
| JP2024521929A (ja) | ２，８－ジアザスピロ［４．５］デカン化合物 | |
| EA050465B1 (ru) | Соединения карбокси-бензимидазола, модулирующие glp-1r | |
| HK1249502B (en) | Pyrido(3,4-d) pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| HK1249502A1 (zh) | 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐 |